Compare JLL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JLL | INSM |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United States | United States |
| Employees | 48000 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 30.1B |
| IPO Year | 1997 | 2000 |
| Metric | JLL | INSM |
|---|---|---|
| Price | $292.10 | $145.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 24 |
| Target Price | ★ $363.17 | $198.04 |
| AVG Volume (30 Days) | 425.7K | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.13 | N/A |
| EPS | ★ 16.40 | N/A |
| Revenue | ★ $26,115,600,000.00 | N/A |
| Revenue This Year | $7.70 | $174.73 |
| Revenue Next Year | $6.91 | $65.13 |
| P/E Ratio | $18.28 | ★ N/A |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $194.36 | $60.40 |
| 52 Week High | $363.06 | $212.75 |
| Indicator | JLL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 48.49 |
| Support Level | $279.24 | $142.99 |
| Resistance Level | $309.79 | $149.08 |
| Average True Range (ATR) | 9.46 | 5.27 |
| MACD | 0.74 | 1.07 |
| Stochastic Oscillator | 36.74 | 65.62 |
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.